_256_384.jpg)
In FY21, the company reported a net profit of Rs 419 crores compared to Rs 101 crores in FY 20 and consolidated total income at Rs 6092 crores, up 19% Y-o-Y
The company proposes to utilise the net proceeds from the fresh issue towards payment of outstanding purchase consideration
With the surge of infections in India in the recent days AmphoTLC will address the country's acute liposomal amphotericin B shortage
The IPO comprises a fresh issue of up to Rs. 11,600 million and an offer for sale of up to 7,305,245 equity shares of Rs. 2 each of Glenmark Life Sciences by Glenmark Pharmaceuticals
TCPCL is the largest and only commercial manufacturer of SDAs for zeolites in India
M&A activity, IPOs and late-stage investments gain momentum as investors prioritize clinical validation, while early-stage biotech firms continue to face funding challenges
New Tracxn report highlights growing investor confidence in automated cell therapy production, with Cellares and Ori Biotech dominating funding and regulatory milestones
Seasoned pharmaceutical R&D leader takes on an expanded leadership role to drive innovation and strengthen Hetero’s advanced formulation development capabilities
Findings show growing optimism across the pharma sector as dealmaking accelerates, innovation strengthens, and companies adapt to tariffs, pricing reforms, and looming patent expirations
Mahler brings more than 20 years of leadership experience spanning cell therapy, biopharmaceutical development, manufacturing, and global business management
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
